Serrao, Juliet M.
Goodchild, Colin S.
Funding for this research was provided by:
Drawbridge Pharmaceuticals P/L
Article History
Received: 24 July 2022
Accepted: 9 December 2022
First Online: 24 December 2022
Declarations
:
: The clinical trial was approved by the Royal Adelaide Hospital human research ethics committee (approval number HREC/17/RAH/523) and also registered with the Australian New Zealand Clinical Trials Registry: registration number ACTRN12618000064202 [Universal Trial Number U1111-1198-0412]; registration date 17/01/2018. All patients in the clinical trial gave written informed consent prior to trial entry. All procedures were performed in accordance with relevant guidelines set out in the Declaration of Helsinki statement of ethical principles for medical research involving human subjects, including research on identifiable human material and data.
: Not applicable.
: JMS and CSG both have equity interests in Drawbridge Pharmaceuticals. Both are cited on Phaxan® patents as inventors and they are both shareholders of Drawbridge Pharmaceuticals to which the Phaxan® patents have been assigned.